NCT01147406View on ClinicalTrials.gov

Safety and Tolerability Study of N6022 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Healthy
Interventions
DRUG

N6022

This is an injectible formulation which will be given at 5, 15 \& 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.

DRUG

Placebo

This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.

Trial Locations (1)

21225

Parexel Early Phase Unit, Baltimore

Sponsors
All Listed Sponsors
lead

Nivalis Therapeutics, Inc.

INDUSTRY

NCT01147406 - Safety and Tolerability Study of N6022 in Healthy Subjects | Biotech Hunter | Biotech Hunter